 Helius Portable Neuromodulation Stimulator PoNSTM device is now authorized to be marketed for the short-term treatment 14 weeks of gait deficit due to mild and moderate symptoms from MS and is to be used in conjunction with physical therapy, in addition to the short-term treatment 14 weeks of chronic balance deficit due to mild-to-moderate traumatic brain injury and is to be used in conjunction with physical therapy. We are very pleased to receive regulatory clearance to market our PoNS Treatment to the approximately 93,500 patients in Canada who suffer from MS, said Philippe Deschamps, Chief Executive Officer of Helius. 